{
    "organizations": [],
    "uuid": "bba3cf616094f40d90fb1189ef5335e75030b3cd",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-mylan-adds-to-growing-womens-healt/brief-mylan-adds-to-growing-womens-healthcare-portfolio-with-launch-of-generic-for-oral-contraceptive-yaz-idUSASC09XA8",
    "ord_in_thread": 0,
    "title": "BRIEF-Mylan Adds To Growing Women's Healthcare Portfolio With Launch Of Generic For Oral Contraceptive Yaz",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 25 (Reuters) - Mylan NV:\n* MYLAN ADDS TO GROWING WOMEN’S HEALTHCARE PORTFOLIO WITH LAUNCH OF GENERIC FOR ORAL CONTRACEPTIVE YAZ®\n* MYLAN NV - U.S. LAUNCH OF DROSPIRENONE AND ETHINYL ESTRADIOL TABLETS USP, 3 MG/0.02 MG, A GENERIC VERSION OF BAYER’S YAZ TABLETS Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-25T19:38:00.000+03:00",
    "crawled": "2018-04-26T20:53:01.050+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "mylan",
        "nv",
        "mylan",
        "add",
        "growing",
        "woman",
        "healthcare",
        "portfolio",
        "launch",
        "generic",
        "oral",
        "contraceptive",
        "mylan",
        "nv",
        "launch",
        "drospirenone",
        "ethinyl",
        "estradiol",
        "tablet",
        "usp",
        "mg",
        "generic",
        "version",
        "bayer",
        "yaz",
        "tablet",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}